Literature DB >> 32940072

Ingestion-time - relative to circadian rhythms - differences in the pharmacokinetics and pharmacodynamics of hypertension medications.

Ramón C Hermida1,2, Ramón G Hermida-Ayala3, Michael H Smolensky2, Artemio Mojón1, José R Fernández1.   

Abstract

INTRODUCTION: Hypertension guidelines do not recommend the time to administer blood pressure (BP)-lowering medications, despite multiple prospective clinical trials reporting both improved normalization of BP 24 h patterning and reduced cardiovascular disease (CVD) events when ingested at bedtime rather than upon awakening. AREAS COVERED: We review: (i) circadian rhythm-dependent influences on the pharmacokinetics (PK) and pharmacodynamics (PD) of hypertension medications; (ii) reports of ingestion-time differences in PK and PD of such therapies; and (iii) (chrono)prevention of CVD morbidity and mortality achieved by the simple and low-cost bedtime hypertension chronotherapy strategy, i.e. scheduling at bedtime ≥1 conventional BP-lowering medications to target asleep BP control of ABPM-diagnosed true arterial hypertension patients. EXPERT OPINION: Proper management of hypertension requires awareness of known ingestion-time differences in both the PK of individual BP-lowering medications and their combinations, which arise from circadian rhythms affecting absorption, distribution, metabolism, and elimination, and their PD, which result from circadian rhythms in mechanisms that regulate the 24 h BP pattern. The vast majority of the multiple published trials document substantially enhanced lowering of asleep BP, increased sleep-time relative BP decline (dipping), and markedly better reduction of CVD morbidity and mortality when hypertension medications and their combinations are ingested at bedtime rather than upon waking.

Entities:  

Keywords:  Ambulatory blood pressure monitoring; asleep blood pressure; bedtime hypertension chronotherapy; cardiovascular risk; chronopharmacodynamics; chronopharmacokinetics; chronopharmacology; hypertension medications

Mesh:

Substances:

Year:  2020        PMID: 32940072     DOI: 10.1080/17425255.2020.1825681

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  3 in total

1.  Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications.

Authors:  Ramón C Hermida; Michael H Smolensky; Horia Balan; Richard J Castriotta; Juan J Crespo; Yaron Dagan; Sherine El-Toukhy; José R Fernández; Garret A FitzGerald; Akio Fujimura; Yong-Jian Geng; Ramón G Hermida-Ayala; Antonio P Machado; Luiz Menna-Barreto; Artemio Mojón; Alfonso Otero; R Daniel Rudic; Eva Schernhammer; Carsten Skarke; Tomoko Y Steen; Martin E Young; Xiaoyun Zhao
Journal:  Chronobiol Int       Date:  2020-12-20       Impact factor: 3.749

Review 2.  Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions.

Authors:  Yong-Jian Geng; Rosalinda Madonna; Ramon C Hermida; Michael H Smolensky
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-06

3.  Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.

Authors:  Nicola Di Trani; Hsuan-Chen Liu; Ruogu Qi; Dixita I Viswanath; Xuewu Liu; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Nanomedicine       Date:  2021-06-22       Impact factor: 6.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.